Whitehawk Therapeutics posts corporate deck highlighting ADC platform and Phase 1 pipeline progress
WHWK•Corporate deck highlights lead ADC programs and pipeline timing
- Whitehawk Therapeutics outlined three lead antibody-drug conjugates, with HWK-007 and HWK-016 in Phase 1.
- Initial Phase 1 data for HWK-007 and HWK-016 targeted for 1H 2027; HWK-206 Phase 1 start expected in Q3 2026.
- HWK-206, a SEZ6 program in IND-enabling, is positioned for SCLC and neuroendocrine tumors; data targeted for 2H 2027.
- Cash balance of USD 190 million as of June 30, 2026; cash runway projected into 2H 2028.
- Pipeline expansion plans include an option with Hangzhou DAC for up to five CPT113-based ADCs, including dual-payload candidates.
